Cardiovascular diseases (CVD) are responsible for the majority of deaths worldwide. Nanotechnology, considered one of the key technologies of the 21st century, is expected to improve the management of CVD.This event on October 13, with leading scientists in the field of cardiology and cardiovascular nanomedicine, provided an overview of the state-of-the-art diagnostics and therapy in CVD, but also answered the most burning questions concerning the potential of novel nanomedical approaches in the management of cardiovascular diseases.
8 highly motivated runners took part in the "3. Lauf gegen Krebs" on 10/13/2016 and could contribute to the fundraising with 97 laps completed.
14 highly motivated runners took part in the "2. Lauf gegen Krebs" on 10/18/2015 and could contribute to the fundraising with 158 laps completed.
Since February 2013, SEON has been participating in the European project titled: “Nanomedicine for target-specific imaging and treatment of atherothrombosis: development and initial clinical feasibility (NanoAthero)”. Within this project, 16 partners from 10 European countries focus their efforts on the development and the characterization of nanosystems for the diagnosis and therapy of cardiovascular diseases.
SEON is involved in two work packages: Design and characterization of nanosystems (WP1) and Preclinical validation of nanosystems (WP2). These work packages are closely related and link researchers from 10 different institutions across Europe. In this context, we are proud to host the next technical meeting of the NanoAthero WP1 and WP2 partners in Erlangen. This meeting will take place on 18th and 19th May 2015, and will be dedicated to discussing research achievements and challenges, project progress, as well as important milestones and deliverables.
Forschungsstiftung Medizin at the Universitätsklinikum Erlangen
IBAN: DE 69 76350000 0000062000
Nanomedizin Prof. Alexiou